Prevalence and 3‐year persistence of human papillomavirus serotypes in asymptomatic patients in Northern Mexico

To investigate clinical outcomes and 3‐year persistence of human papillomavirus (HPV) infections among women in Mexico.

[1]  J. Semmens,et al.  Spontaneous regression of CIN2 in women aged 18–24 years: a retrospective study of a state‐wide population in Western Australia , 2016, Acta obstetricia et gynecologica Scandinavica.

[2]  R. von Wasielewski,et al.  CIN III lesions and regression: retrospective analysis of 635 cases , 2015, BMC Infectious Diseases.

[3]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[4]  R. López-Romero,et al.  Human papillomavirus genotypes among females in Mexico: a study from the Mexican institute for social security. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[5]  M. Anaya-Ruiz,et al.  Cervical cancer trends in Mexico: incidence, mortality and research output. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[6]  Jack Cuzick,et al.  Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[7]  M. Patarroyo,et al.  Persistence, clearance and reinfection regarding six high risk human papillomavirus types in Colombian women: a follow-up study , 2014, BMC Infectious Diseases.

[8]  M. Mikami,et al.  Potential impact of combined high‐ and low‐risk human papillomavirus infection on the progression of cervical intraepithelial neoplasia 2 , 2014, The journal of obstetrics and gynaecology research.

[9]  J. Berkhof,et al.  Prospective follow‐up of 2,065 young unscreened women to study human papillomavirus incidence and clearance , 2013, International journal of cancer.

[10]  T. Weiss,et al.  Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease , 2012, Infectious Agents and Cancer.

[11]  H. Cubie,et al.  Human papillomavirus vaccine introduction--the first five years. , 2012, Vaccine.

[12]  Peng Guan,et al.  Human papillomavirus types in 115,789 HPV‐positive women: A meta‐analysis from cervical infection to cancer , 2012, International journal of cancer.

[13]  M. Lizano,et al.  Geographical variation in human papillomavirus prevalence in Mexican women with normal cytology. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[14]  E. Lazcano-Ponce,et al.  Nuevos paradigmas y desafíos en la prevención y control del cáncer de cuello uterino en América Latina , 2010 .

[15]  M. Sánchez-Garza,et al.  Infectious Agents and Cancer BioMed Central , 2008 .

[16]  J. Baak,et al.  Cervical intraepithelial neoplasia grade 3 lesions can regress , 2007, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[17]  M. McLemore.  Gardasil: Introducing the new human papillomavirus vaccine. , 2006, Clinical journal of oncology nursing.

[18]  P. Snijders,et al.  Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening , 2005, British Journal of Cancer.

[19]  A. Giuliano,et al.  Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. , 2002, The Journal of infectious diseases.

[20]  Mark Sherman,et al.  The 2001 Bethesda System: terminology for reporting results of cervical cytology. , 2002, JAMA.

[21]  N. Muñoz,et al.  Epidemiology of HPV infection among Mexican women with normal cervical cytology , 2001, International journal of cancer.

[22]  R. Burk,et al.  Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. , 1995, Journal of the National Cancer Institute.

[23]  M. Evander,et al.  Human Papillomavirus Infection Is Transient in Young Women: A PopulationBased Cohort Study , 1995 .

[24]  Y. Hu,et al.  Application of human papillomavirus in screening for cervical cancer and precancerous lesions. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[25]  Biological agents. Volume 100 B. A review of human carcinogens. , 2012, IARC monographs on the evaluation of carcinogenic risks to humans.

[26]  G. Sánchez,et al.  [New paradigms and challenges in cervical cancer prevention and control in Latin America]. , 2010, Salud publica de Mexico.

[27]  M. Evander,et al.  Human papillomavirus infection is transient in young women: a population-based cohort study. , 1995, The Journal of infectious diseases.